Flagship Harbor Advisors’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $549K | Sell |
2,895
-104
| -3% | -$19.6K | 0.02% | 491 |
|
|
2026
Q1 | $591K | Sell |
2,999
-488
| -14% | -$94.1K | 0.03% | 437 |
|
|
2025
Q4 | $641K | Sell |
3,487
-270
| -7% | -$47.4K | 0.03% | 390 |
|
|
2025
Q3 | $576K | Sell |
3,757
-119
| -3% | -$18K | 0.03% | 459 |
|
|
2025
Q2 | $542K | Sell |
3,876
-8
| -0.2% | -$1.12K | 0.03% | 450 |
|
|
2025
Q1 | $571K | Sell |
3,884
-27
| -0.7% | -$3.91K | 0.03% | 404 |
|
|
2024
Q4 | $512K | Sell |
3,911
-100
| -2% | -$14K | 0.03% | 422 |
|
|
2024
Q3 | $625K | Buy |
4,011
+54
| +1% | +$8.72K | 0.03% | 365 |
|
|
2024
Q2 | $617K | Hold |
3,957
| – | – | 0.04% | 353 |
|
|
2024
Q1 | $536K | Buy |
3,957
+93
| +2% | +$12.3K | 0.03% | 367 |
|
|
2023
Q4 | $520K | Buy |
3,864
+28
| +0.7% | +$3.64K | 0.04% | 352 |
|
|
2023
Q3 | $520K | Buy |
3,836
+5
| +0.1% | +$683 | 0.04% | 319 |
|
|
2023
Q2 | $548K | Sell |
3,831
-25
| -0.6% | -$3.68K | 0.05% | 308 |
|
|
2023
Q1 | $535K | Sell |
3,856
-140
| -4% | -$18.8K | 0.05% | 340 |
|
|
2022
Q4 | $542K | Sell |
3,996
-62
| -2% | -$7.78K | 0.06% | 317 |
|
|
2022
Q3 | $445K | Sell |
4,058
-14
| -0.3% | -$1.78K | 0.05% | 336 |
|
|
2022
Q2 | $538K | Sell |
4,072
-402
| -9% | -$52.7K | 0.06% | 314 |
|
|
2022
Q1 | $594K | Sell |
4,474
-15
| -0.3% | -$1.8K | 0.06% | 315 |
|
|
2021
Q4 | $523K | Buy |
4,489
+419
| +10% | +$49.3K | 0.05% | 356 |
|
|
2021
Q3 | $488K | Hold |
4,070
| – | – | 0.05% | 354 |
|
|
2021
Q2 | $488K | Sell |
4,070
-542
| -12% | -$59.5K | 0.05% | 355 |
|
|
2021
Q1 | $459K | Sell |
4,612
-493
| -10% | -$49.6K | 0.05% | 371 |
|
|
2020
Q4 | $510K | Sell |
5,105
-793
| -13% | -$84K | 0.06% | 299 |
|
|
2020
Q3 | $646K | Buy |
5,898
+1,104
| +23% | +$123K | 0.09% | 220 |
|
|
2020
Q2 | $507K | Buy |
4,794
+436
| +10% | +$45K | 0.07% | 252 |
|
|
2020
Q1 | $389K | Buy |
4,358
+697
| +19% | +$65.6K | 0.08% | 246 |
|
|
2019
Q4 | $365K | Buy |
3,661
+37
| +1% | +$3.48K | 0.06% | 298 |
|
|
2019
Q3 | $323K | Buy |
3,624
+152
| +4% | +$13.2K | 0.06% | 296 |
|
|
2019
Q2 | $286K | Buy |
3,472
+100
| +3% | +$7.84K | 0.06% | 315 |
|
|
2019
Q1 | $272K | Sell |
3,372
-49
| -1% | -$3.86K | 0.06% | 319 |
|
|
2018
Q4 | $259K | Sell |
3,421
-2,949
| -46% | -$230K | 0.06% | 296 |
|
|
2018
Q3 | $503K | Sell |
6,370
-952
| -13% | -$72K | 0.09% | 230 |
|
|
2018
Q2 | $514K | Buy |
7,322
+4,209
| +135% | +$303K | 0.1% | 210 |
|
|
2018
Q1 | $216K | Sell |
3,113
-77
| -2% | -$5.33K | 0.06% | 317 |
|
|
2017
Q4 | $227K | Buy |
+3,190
| New | +$215K | 0.07% | 315 |
|
Other funds holding AZN
EP
IA
Flagship Harbor Advisors's AZN Position: Q2 2026 in Review
Flagship Harbor Advisors reduced its AstraZeneca (AZN) stake by 3.5% in Q2 2026, selling an estimated $19.6K and leaving 2,895 shares worth $549K. The position accounts for 0.02% of the portfolio, ranked #491.
Flagship Harbor Advisors first reported a position in AZN in Q4 2017 and has held it in 35 quarters since. The position peaked at $646K in Q3 2020. 1,495 funds tracked by Wall St. Rank hold AZN as of Q2 2026.
- Flagship Harbor Advisors held 2,895 shares of AstraZeneca worth $549K as of Q2 2026.
- Flagship Harbor Advisors sold 104 AstraZeneca shares in Q2 2026, an estimated $19.6K.
- AstraZeneca made up 0.02% of Flagship Harbor Advisors's portfolio in Q2 2026, its #491 holding.
- Flagship Harbor Advisors first reported a position in AstraZeneca in Q4 2017 and has held it in 35 quarters since.
- Flagship Harbor Advisors's AstraZeneca position peaked at $646K in Q3 2020.
- 1,495 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.
Based on Flagship Harbor Advisors's 13F filing for Q2 2026, filed 22 Jul 2026.